E25 - Eribulin s Effect on Breast Cancer Plasticity

E25   |  12 min   |   Latest   |  Publication Link Podcast based on: Bidgood, C.L.; Morera, E.; Jaradi, B.; van Wyngaard, T.; Koikalethu, A.T.; Bock, N.; Agarwal, V.; Redfern, A.D.; Thompson, E.W. Effects of Eribulin on Epithelial–Mesenchymal Plasticity in Patient-Derived Breast Cancer Cultures and Excised Tissues. Cancers 2026, 18, 598. https://doi.org/10.3390/cancers18040598 Type: Article  |  Publication date: 11 February 2026 Summary: Eribulin is an approved therapy for the treatment of breast cancer which has been shown to reverse the epithelial-to-mesenchymal transition (EMT) and improve the efficacy of standard chemotherapies in cell lines, animal studies, and clinical specimens. Tumour EMT status has also been linked to eribulin efficacy. Based on this, we evaluated the effects of eribulin in patient-derived breast cancer cultures and a triple-negative breast cancer cell line to assess changes to EMT and therapy response. We further identified the induction of epithelial-like characteristics, including E-cadherin expression in a patient-derived HER2+ primary tissue with a predominantly mesenchymal phenotype following longitudinal eribulin exposure. Additionally, we compared EMT marker expression in breast cancers treated with standard-of-care neoadjuvant docetaxel, Adriamycin and cyclophosphamide (TAC) therapy with that observed in the neoadjuvant eribulin clinical trial. Keywords: breast cancer; eribulin; EMT; chemoresistance   Disclaimer: This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.